Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance

OBJECTIVE: Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively-activated mutation of EGFR that contributes to the malignant progression of glioblastoma multiforme (GBM). Temozolomide (TMZ) is a standard chemotherapeutic for GBM, but TMZ treatment benefits are compromised by c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Junhu, Tong, Fei, Zhao, Jixing, Cui, Xiaoteng, Wang, Yunfei, Wang, Guangxiu, Kang, Chunsheng, Liu, Xiaomin, Wang, Qixue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246439/
https://www.ncbi.nlm.nih.gov/pubmed/37283490
http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246439/
https://www.ncbi.nlm.nih.gov/pubmed/37283490
http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0011

Ejemplares similares